¼¼°èÀÇ ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀå : µ¿Çâ, ¿¹Ãø, °æÀï ºÐ¼®(-2030³â)
Influenza Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2030
»óǰÄÚµå : 1559912
¸®¼­Ä¡»ç : Lucintel
¹ßÇàÀÏ : 2024³â 09¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 150 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,850 £Ü 7,017,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. PDF ÆÄÀÏÀº DRM(µðÁöÅÐ ÀúÀÛ±Ç °ü¸® ½Ã½ºÅÛ)ÀÌ ÀåÂøµÇ¾î ÀÖ½À´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,800 £Ü 8,392,000
PDF (2 Users License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 2¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. PDF ÆÄÀÏÀº DRM(µðÁöÅÐ ÀúÀÛ±Ç °ü¸® ½Ã½ºÅÛ)ÀÌ ÀåÂøµÇ¾î ÀÖ½À´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,700 £Ü 9,694,000
PDF (5 Users License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. PDF ÆÄÀÏÀº DRM(µðÁöÅÐ ÀúÀÛ±Ç °ü¸® ½Ã½ºÅÛ)ÀÌ ÀåÂøµÇ¾î ÀÖ½À´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,850 £Ü 12,805,000
PDF (Corporate License) help
PDF º¸°í¼­¸¦ ±â¾÷ ³» ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÀÌ¿ë Àοø¿¡ Á¦ÇÑÀº ¾øÀ¸³ª, ±¹³»¿¡ ÀÖ´Â »ç¾÷À常 ÇØ´çµÇ¸ç, ÇØ¿Ü ÁöÁ¡ µîÀº Æ÷ÇÔµÇÁö ¾Ê½À´Ï´Ù. PDF ÆÄÀÏÀº DRM(µðÁöÅÐ ÀúÀÛ±Ç °ü¸® ½Ã½ºÅÛ)ÀÌ ÀåÂøµÇ¾î ÀÖ½À´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°è ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀå ±Ô¸ð´Â 2024-2030³â¿¡ °ÉÃÄ CAGR 6.8%·Î ¼ºÀåÇÏ¿© 2030³â±îÁö ÃßÁ¤ 112¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. ÀÌ ½ÃÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎÀº º¸´Ù È¿°úÀûÀ̰í ħ½À¼ºÀÌ ³·Àº ÀÎÇ÷翣ÀÚ ¹é½Å¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí, ÀÎÇ÷翣ÀÚ ¹é½ÅÀÇ ÀÌÁ¡¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í, ÀÎÇ÷翣ÀÚ ¹é½Å Á¢Á¾À» ÃËÁøÇϱâ À§ÇÑ Á¤ºÎÀÇ Áö¿øÃ¥ µîÀÔ´Ï´Ù. ¼¼°è ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀåÀÇ ¹Ì·¡´Â º´¿ø¡¤¼Ò¸Å ¾à±¹°ú Á¤ºÎ °ø±Þ ä³Î¿¡¼­ÀÇ ±âȸ°¡ À¯¸Á½ÃµÇ°í ÀÖ½À´Ï´Ù.

ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀåÀÇ »õ·Î¿î µ¿Çâ

ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀåÀÇ »õ·Î¿î µ¿ÇâÀº ¹é½Å ±â¼úÀÇ Çõ½Å, Á¢±Ù¼º È®´ë, °øÁß º¸°Ç Àü·«ÀÇ ÁøÈ­¸¦ ¹Ý¿µÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼´Â ÀÎÇ÷翣ÀÚÀÇ ¿¹¹æ°ú Ä¡·áÀÇ ¹Ì·¡¸¦ ¼¼°èÀûÀ¸·Î Çü¼ºÇϰí ÀÖ½À´Ï´Ù.

4°¡ ¹é½Å°ú °í¿ë·® ¹é½Å °³¹ß, ¹é½Å ±â¼ú Çõ½Å¿¡ ÁÖ·Â, ¿¬ 1ȸ ¹é½Å Á¢Á¾ÀÇ Áß½Ã, ÃæºÐÇÑ ÀÇ·á ¼­ºñ½º¸¦ ¹ÞÁö ¾ÊÀº Áö¿ªÀ¸·ÎÀÇ È®´ë, µðÁöÅÐ Çコ ¼Ö·ç¼Ç°úÀÇ ÅëÇÕ µî ½ÅÈï±¹ ½ÃÀå µ¿ÇâÀº µ¶°¨ ¹é½Å ½ÃÀåÀ» À籸¼ºÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀº ¹é½ÅÀÇ È¿´É, Á¢±Ù¼º ¹× °øÁߺ¸°ÇÀü·«À» °­È­ÇÕ´Ï´Ù.

ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀåÀÇ ÃÖ±Ù µ¿Çâ

ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀåÀÇ ÃÖ±Ù µ¿ÇâÀº ±â¼ú Áøº¸, ±ÔÁ¦ °»½Å, °øÁß º¸°Ç Àü·«ÀÇ °³¼±¿¡ ÀÇÇØ µÎµå·¯Áö°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÁøÀüÀº ¹é½ÅÀÇ È¿´É°ú Á¢±Ù¼º¿¡ º¯È­¸¦ °¡Á®¿É´Ï´Ù.

4°¡ ¹é½ÅÀÇ µµÀÔ, °í¿ë·® ¹é½Å ¹× º¸Á¶Á¦ ¹é½ÅÀÇ Áøº¸, Á¢±Ù ÇÁ·Î±×·¥ÀÇ È®´ë, »õ·Î¿î Á¦Á¦ÀÇ ÃâÇö, ¼¼°èÀûÀÎ Çù·Â µî ÃÖ±ÙÀÇ µ¿ÇâÀº ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀå¿¡ Å« ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Áøº¸´Â ¹é½ÅÀÇ È¿´É, Á¢±Ù¼º ¹× °øÁߺ¸°ÇÀÇ Àü¹ÝÀûÀÎ ¼º°ú¸¦ Çâ»ó½Ãŵ´Ï´Ù.

ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀåÀÇ Àü·«Àû ¼ºÀå ±âȸ

ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀå¿¡¼­ÀÇ Àü·«Àû ¼ºÀå ±âȸ´Â ¹é½Å ±â¼úÀÇ Áøº¸, ¼¼°èÀÇ ¹é½Å Á¢Á¾ Ȱµ¿ Áõ°¡, °øÁß º¸°Ç ¿ä±¸ÀÇ ÁøÈ­¿¡ ÀÇÇØ ÃÊ·¡µË´Ï´Ù. ÀÌ·¯ÇÑ ±âȸ´Â ½ÃÀå È®´ë¿Í °Ç°­ °á°ú °³¼±ÀÇ °¡´É¼ºÀ» º¸¿©ÁÝ´Ï´Ù.

ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀåÀÇ Àü·«Àû ¼ºÀå ±âȸ´Â ½ÅÈï±¹ ½ÃÀå ÁøÃâ, Â÷¼¼´ë ¹é½Å °³Ã´, °øÁß º¸°Ç ÇÁ·Î±×·¥°úÀÇ ÅëÇÕ, µðÁöÅÐ °Ç°­ ÁøÀü, Àü·«Àû ÆÄÆ®³Ê½Ê µîÀ» Æ÷ÇÔÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ±âȸ´Â ½ÃÀå È®´ë¸¦ ÃËÁøÇϰí, ¹é½Å¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» Çâ»ó½Ã۰í, °øÁß º¸°ÇÀÇ Àüü ¼º°ú¸¦ Çâ»ó½Ãŵ´Ï´Ù.

ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀå ¼ºÀå ÃËÁø¿äÀΡ¤°úÁ¦

ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀåÀº ±â¼ú Áøº¸, °æÁ¦ ¿äÀÎ, ±ÔÁ¦ ¹®Á¦ µî ´Ù¾çÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀΰú °úÁ¦ÀÇ ¿µÇâÀ» ¹Þ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿ä¼Ò¸¦ ÀÌÇØÇÏ´Â °ÍÀº ½ÃÀåÀ» Ž»öÇÏ°í ¼ºÀåÀ» °¡¼ÓÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÕ´Ï´Ù.

ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀåÀ» °ßÀÎÇÏ´Â ¿äÀÎÀº ´ÙÀ½°ú °°½À´Ï´Ù.

1. ¹é½Å °³¹ß¿¡ À־ÀÇ ±â¼úÀÇ Áøº¸: ¹é½Å °³¹ß¿¡ À־ÀÇ ±â¼ú Áøº¸: »õ·Î¿î Á¦Á¦³ª Àü´Þ ¹æ¹ýÀÇ °³¼± µî, ¹é½Å °³¹ß¿¡ À־ÀÇ ±â¼ú Áøº¸°¡ ½ÃÀå °³Ã´ÀÇ ¿øµ¿·ÂÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ Çõ½ÅÀº ¹é½ÅÀÇ È¿´ÉÀ» ³ôÀÌ°í ½ÅÁ¾ ÀÎÇ÷翣ÀÚ¿¡ ´ëÀÀÇÔÀ¸·Î½á Àüü °øÁß º¸°ÇÀÇ ¼º°ú¸¦ Çâ»ó½Ãŵ´Ï´Ù.

2. ÀÏ¹Ý ½Ã¹ÎÀÇ ÀÇ½Ä Çâ»ó°ú °Ç°­ Ä·ÆäÀÎ: ÀÎÇ÷翣ÀÚ ¹é½Å Á¢Á¾ÀÇ Á߿伺¿¡ °üÇÑ ÀÏ¹Ý ½Ã¹ÎÀÇ ÀÇ½Ä Çâ»ó°ú °Ç°­ Ä·ÆäÀÎÀÌ ¹é½Å ¼·ÃëÀ²À» ³ôÀÔ´Ï´Ù. ±³À° ÀÌ´Ï¼ÅÆ¼ºê¿Í ¸ñÇ¥·Î »ïÀº Ä·ÆäÀÎÀº ¹é½Å Á¢Á¾·ü Çâ»ó°ú °èÀý µ¶°¨ ¿¹¹æ °³¼±¿¡ ±â¿©ÇÕ´Ï´Ù.

3. Á¤ºÎÀÇ ÀÚ±Ý Áö¿ø ¹× º¸Á¶±Ý: Á¤ºÎÀÇ ÀÚ±Ý Áö¿ø ¹× º¸Á¶±ÝÀº ÀÎÇ÷翣ÀÚ ¿¹¹æ Á¢Á¾ ÇÁ·Î±×·¥À» Áö¿øÇÏ°í ¹é½ÅÀ» º¸´Ù ½±°Ô ÀÔ¼öÇÒ ¼ö ÀÖµµ·Ï ÇÕ´Ï´Ù. ÀçÁ¤ Áö¿øÀº ¹é½Å ºñ¿ëÀ» ÁÙÀ̰í, ƯÈ÷ ¼­ºñ½º°¡ ÃæºÐÇÏÁö ¾ÊÀº »ç¶÷µé°ú À§ÇèÀÌ ³ôÀº »ç¶÷µé¿¡°Ô ´õ ±¤¹üÀ§ÇÑ Á¢Á¾À» ÃËÁøÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù.

4. ÀÎÇ÷翣ÀÚ ¹× °ü·Ã ÇÕº´ÁõÀÇ ¹ß»ý·ü Áõ°¡: ÀÎÇ÷翣ÀÚ ¹× °ü·Ã ÇÕº´Áõ Áõ°¡·Î È¿°úÀûÀÎ ¹é½Å ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÎÇ÷翣ÀÚÀÇ À¯Çà°ú ÁßÁõÈ­ »ç·Ê Áõ°¡´Â ¹é½Å Á¢Á¾ Àü·« °³¼±ÀÇ Çʿ伺À» ºÎ°¢½ÃŰ°í ½ÃÀå ¼ºÀå¿¡ ±â¿©ÇÕ´Ï´Ù.

5. ±¹Á¦ º¸°Ç ÆÄÆ®³Ê½Ê°ú Çù·Â °ü°è: ¼¼°è °Ç°­ÀÇ ÆÄÆ®³Ê½Ê°ú Çù·Â °ü°è´Â ¹é½ÅÀÇ À¯Åë°ú Á¢±ÙÀ» °­È­ÇÕ´Ï´Ù. Á¤ºÎ, NGO ¹× ¹Î°£ ´ÜüÀÇ Çù·ÂÀº ¹é½ÅÀÇ °¡¿ë¼ºÀ» Çâ»ó½ÃŰ°í ¼¼°è ÀÎÇ÷翣ÀÚ ¿¹¹æ ³ë·ÂÀ» ÃËÁøÇÕ´Ï´Ù.

ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀåÀÇ °úÁ¦´Â ´ÙÀ½°ú °°½À´Ï´Ù.

1. ¹é½Å¿¡ ´ëÇÑ ÁÖÀú¿Í À߸øµÈ Á¤º¸ : ¿¹¹æÁ¢Á¾ÀÇ ÁÖÀú¿Í À߸øµÈ Á¤º¸´Â ¹é½ÅÁ¢Á¾·ü Çâ»óÀÇ °úÁ¦°¡ µÇ°í ÀÖ½À´Ï´Ù. ¿¹¹æ Á¢Á¾·üÀ» Çâ»ó½ÃŰ°í ¿¹¹æ Á¢Á¾ ÇÁ·Î±×·¥À» ¼º°ø½Ã۱â À§Çؼ­´Â ÀÏ¹Ý ½Ã¹ÎµéÀÇ ¿ì·Á¸¦ ÇØ°áÇϰí Á¤È®ÇÑ Á¤º¸¸¦ Á¦°øÇÏ´Â °ÍÀÌ ÇʼöÀûÀÔ´Ï´Ù.

2. ³ôÀº ¹é½Å ºñ¿ë: ¹é½Å ºñ¿ëÀÇ »ó½ÂÀº ƯÈ÷ Àú¼Òµæ Áö¿ª¿¡¼­ ¹é½Å Á¢Á¾À» Á¦ÇÑÇÒ ¼ö ÀÖ½À´Ï´Ù. ¹é½ÅÀÇ °¡¿ë¼ºÀ» °³¼±ÇÏ°í º¸´Ù ±¤¹üÀ§ÇÑ Á¢Á¾·üÀ» ´Þ¼ºÇϱâ À§Çؼ­´Â °¡°Ý ¹®Á¦¸¦ ÇØ°áÇÏ´Â °ÍÀÌ ¸Å¿ì Áß¿äÇÕ´Ï´Ù.

3. ±ÔÁ¦ ¹× ±ÔÁ¤ Áؼö ¹®Á¦: º¹ÀâÇÑ ±ÔÁ¤ ¹× ±ÔÁ¤ Áؼö ¹®Á¦¸¦ ±Øº¹ÇÏ´Â °ÍÀº ¾î·Æ½À´Ï´Ù. Áö¿ªº°·Î ´Ù¸¥ ±ÔÁ¦¸¦ È®½ÇÇÏ°Ô ÁؼöÇÏ¸é ¹é½Å °³¹ß°ú ½ÃÀå ÁøÀÔ¿¡ º¹À⼺ÀÌ »ý±é´Ï´Ù.

ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎÀ¸·Î´Â ±â¼ú Áøº¸, »çȸÀû ÀÎÁöµµ Çâ»ó, Á¤ºÎÀÇ ÀÚ±Ý Áö¿ø, ÀÎÇ÷翣ÀÚ ÀÌȯÀ² Áõ°¡, ±¹Á¦ º¸°Ç ÆÄÆ®³Ê½Ê µîÀÌ ÀÖ½À´Ï´Ù. ÁÖ¿ä °úÁ¦·Î´Â ¿¹¹æ Á¢Á¾, °íºñ¿ë, ±ÔÁ¦ º¹À⼺ µîÀÌ ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀΰú °úÁ¦¸¦ ´Ù·ç´Â °ÍÀº ½ÃÀå ¼ºÀå°ú °øÁß º¸°Ç Çâ»ó¿¡ ÇʼöÀûÀÔ´Ï´Ù.

ºÎ¹®º° ÀÎÇ÷翣ÀÚ ¹é½Å

º» Á¶»ç¿¡¼­´Â ¼¼°èÀÇ ÀÎÇ÷翣ÀÚ ¹é½ÅÀÇ ¹é½Å À¯Çüº°, À¯Åë ä³Îº°, Áö¿ªº° ¿¹ÃøÀ» Á¦°øÇÕ´Ï´Ù.

ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀåÀÇ ±¹°¡º° Àü¸Á

ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀåÀÇ ÃÖ±Ù µ¿ÇâÀº ¹é½Å ±â¼úÀÇ ¹ßÀü, ±ÔÁ¦ º¯°æ, ¼¼°è ¹é½Å Á¢Á¾ Àü·«¿¡ ÁßÁ¡À» µÓ´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀº ¹Ì±¹, Áß±¹, µ¶ÀÏ, Àεµ, ÀϺ»À» Æ÷ÇÔÇÑ ÁÖ¿ä Áö¿ª ½ÃÀå »óȲÀ» Çü¼ºÇϰí ÀÖ½À´Ï´Ù.

FAQ

Q.1 ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀå ±Ô¸ð´Â?

A1. ¼¼°è ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀåÀº 2030³â±îÁö ¿¹»ó 112¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Q.2 ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀåÀÇ ¼ºÀå ¿¹ÃøÀº?

A2. ¼¼°è ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀåÀº 2024-2030³â¿¡ °ÉÃÄ CAGR 6.8%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Q.3 ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀå ¼ºÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÁÖ¿ä ÃËÁø¿äÀÎÀº ¹«¾ùÀΰ¡?

A3. ÀÌ ½ÃÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎÀº º¸´Ù È¿°úÀûÀ̰í ħ½À¼ºÀÌ ³·Àº ÀÎÇ÷翣ÀÚ ¹é½Å¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí, ÀÎÇ÷翣ÀÚ ¹é½ÅÀÇ ÀÌÁ¡¿¡ ´ëÇÑ ÀǽÄÀÌ Áõ°¡Çϰí, ÀÎÇ÷翣ÀÚ ¹é½Å Á¢Á¾À» ÃËÁøÇϱâ À§ÇÑ Á¤ºÎÀÇ Áö¿øÃ¥ÀÔ´Ï´Ù.

Q4. ½ÃÀåÀÇ ÁÖ¿ä ºÎ¹®Àº :

A4. ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀåÀÇ ¹Ì·¡´Â º´¿ø, ¼Ò¸Å ¾à±¹ ¹× Á¤ºÎ °ø±Þ ä³ÎÀÇ ±âȸ¿¡ À¯¸ÁÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

Q5. ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷Àº :

A5. ÁÖ¿ä ÀÎÇ÷翣ÀÚ ¹é½Å ±â¾÷Àº ´ÙÀ½°ú °°½À´Ï´Ù:

Q6. ¾ÕÀ¸·Î °¡Àå Å« ½ÃÀå ºÎ¹®Àº :

A6. ºÒȰ¼ºÈ­ ¹é½ÅÀº ±× ¾ÈÀü¼º°ú È¿´É¿¡¼­ÀÇ ¼ö¿ä°¡ ´Ã¾î³ª°í ÀÖÀ¸¸ç ¿¹Ãø±â°£ µ¿¾È ³ôÀº ¼ºÀåÀÌ ¿¹»óµÉ °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù.

Q7. ½ÃÀå¿¡¼­ ÇâÈÄ 5³â°£ ÃÖ´ë°¡ µÉ °ÍÀ¸·Î ¿¹»óµÇ´Â Áö¿ªÀº:

A7. ºÏ¹Ì´Â ÀÎÇ÷翣ÀÚÀÇ À¯º´·üÀÌ ³ô°í °Ç°­ °ü¸® ½Ã½ºÅÛÀÌ È®¸³µÇ°í ¹é½Å Á¢Á¾¿¡ ´ëÇÑ ¼±È£µµ°¡ ³ô±â ¶§¹®¿¡ ¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù.

Q8. º¸°í¼­ »ç¿ëÀÚ Á¤ÀÇ´Â °¡´ÉÇմϱî?

A8. ±×·¸½À´Ï´Ù, Ãß°¡ ºñ¿ë ¾øÀÌ 10% ÁÖ¹®À» ¹Þ¾Æ¼­ ¸¸µì´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ¼¼°èÀÇ ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀå : ½ÃÀå ¿ªÇÐ

Á¦3Àå ½ÃÀå µ¿Çâ°ú ¿¹Ãø ºÐ¼®, 2018-2030³â

Á¦4Àå ½ÃÀå µ¿Çâ°ú ¿¹Ãø ºÐ¼® : Áö¿ªº°, 2018-2030³â

Á¦5Àå °æÀï ºÐ¼®

Á¦6Àå ¼ºÀå ±âȸ¿Í Àü·« ºÐ¼®

Á¦7Àå ÁÖ¿ä ±â¾÷ÀÇ ±â¾÷ ÇÁ·ÎÆÄÀÏ

JHS
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Influenza Vaccine Trends and Forecast

The future of the global influenza vaccine market looks promising with opportunities in the hospital & retail pharmacy and government supplier channels. The global influenza vaccine market is expected to reach an estimated $11.2 billion by 2030 with a CAGR of 6.8% from 2024 to 2030. The major drivers for this market are rising demand for more effective and less invasive influenza vaccines, growing awareness of the benefits of influenza vaccines, and supportive government initiatives to promote influenza vaccination.

Emerging Trends in the Influenza Vaccine Market

Emerging trends in the influenza vaccine market reflect innovations in vaccine technology, expanded access, and evolving public health strategies. These trends are shaping the future of influenza prevention and treatment globally.

Emerging trends such as the development of quadrivalent and high-dose vaccines, focus on vaccine innovation, increased emphasis on annual vaccination, expansion to underserved areas, and integration with digital health solutions are reshaping the influenza vaccine market. These trends enhance vaccine effectiveness, accessibility, and overall public health strategies.

Recent Developments in the Influenza Vaccine Market

Recent developments in the influenza vaccine market are marked by technological advancements, regulatory updates, and improved public health strategies. These developments are driving changes in vaccine effectiveness and accessibility.

Recent developments such as the introduction of quadrivalent vaccines, advancements in high-dose and adjuvanted vaccines, expansion of access programs, emergence of new formulations, and global collaboration are significantly impacting the influenza vaccine market. These advancements enhance vaccine effectiveness, accessibility, and overall public health outcomes.

Strategic Growth Opportunities for Influenza Vaccine Market

Strategic growth opportunities in the influenza vaccine market are driven by advancements in vaccine technology, increased global vaccination efforts, and evolving public health needs. These opportunities present potential for market expansion and improved health outcomes.

Strategic growth opportunities in the influenza vaccine market include expansion into emerging markets, development of next-generation vaccines, integration with public health programs, advancements in digital health, and strategic partnerships. These opportunities drive market expansion, improve vaccine accessibility, and enhance overall public health outcomes.

Influenza Vaccine Market Driver and Challenges

The influenza vaccine market is influenced by a range of drivers and challenges, including technological advancements, economic factors, and regulatory issues. Understanding these factors is crucial for navigating the market and fostering growth.

The factors responsible for driving the influenza vaccine market include:

1. Technological Advancements in Vaccine Development: Technological advancements in vaccine development, such as new formulations and improved delivery methods, drive market growth. These innovations enhance vaccine efficacy and address emerging influenza strains, improving overall public health outcomes.

2. Increased Public Awareness and Health Campaigns: Increased public awareness and health campaigns about the importance of influenza vaccination boost vaccine uptake. Educational initiatives and targeted campaigns contribute to higher vaccination rates and better prevention of seasonal flu.

3. Government Funding and Subsidies: Government funding and subsidies support influenza vaccination programs and make vaccines more accessible. Financial support helps reduce vaccine costs and promotes broader coverage, particularly in underserved and high-risk populations.

4. Rising Incidence of Influenza and Related Complications: The rising incidence of influenza and related complications drives demand for effective vaccines. Increased flu outbreaks and severe cases highlight the need for improved vaccination strategies and contribute to market growth.

5. Global Health Partnerships and Collaborations: Global health partnerships and collaborations enhance vaccine distribution and access. Collaborative efforts between governments, NGOs, and private organizations improve vaccine availability and facilitate global influenza prevention initiatives.

Challenges in the influenza vaccine market are:

1. Vaccine Hesitancy and Misinformation: Vaccine hesitancy and misinformation pose challenges to increasing vaccination rates. Addressing public concerns and providing accurate information are essential for improving vaccine uptake and ensuring the success of vaccination programs.

2. High Vaccine Costs: High vaccine costs can limit access, particularly in low-income regions. Addressing affordability issues is crucial for improving vaccine accessibility and achieving broader coverage.

3. Regulatory and Compliance Challenges: Navigating complex regulatory and compliance requirements can be challenging. Ensuring adherence to varying regulations across regions adds complexity to vaccine development and market entry.

Major drivers of the influenza vaccine market include technological advancements, increased public awareness, government funding, rising influenza incidence, and global health partnerships. Key challenges include vaccine hesitancy, high costs, and regulatory complexities. Addressing these drivers and challenges is essential for market growth and improving public health outcomes.

List of Influenza Vaccine Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies influenza vaccine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the influenza vaccine companies profiled in this report include-

Influenza Vaccine by Segment

The study includes a forecast for the global influenza vaccine by vaccine type, distribution channel, and region.

Influenza Vaccine Market by Vaccine Type [Analysis by Value from 2018 to 2030]:

Influenza Vaccine Market by Distribution Channel [Analysis by Value from 2018 to 2030]:

Influenza Vaccine Market by Region [Analysis by Value from 2018 to 2030]:

Country Wise Outlook for the Influenza Vaccine Market

Recent developments in the influenza vaccine market highlight advancements in vaccine technology, regulatory changes, and global vaccination strategies. These developments are shaping the market landscape in key regions including the United States, China, Germany, India, and Japan.

Features of the Global Influenza Vaccine Market

Market Size Estimates: Influenza vaccine market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Influenza vaccine market size by vaccine type, distribution channel, and region in terms of value ($B).

Regional Analysis: Influenza vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different vaccine types, distribution channels, and regions for the influenza vaccine market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the influenza vaccine market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this market or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

FAQ

Q.1 What is the influenza vaccine market size?

Answer: The global influenza vaccine market is expected to reach an estimated $11.2 billion by 2030.

Q.2 What is the growth forecast for influenza vaccine market?

Answer: The global influenza vaccine market is expected to grow with a CAGR of 6.8% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the influenza vaccine market?

Answer: The major drivers for this market are rising demand for more effective and less invasive influenza vaccines, growing awareness of the benefits of influenza vaccines, and supportive government initiatives to promote influenza vaccination.

Q4. What are the major segments for influenza vaccine market?

Answer: The future of the influenza vaccine market looks promising with opportunities in the hospital & retail pharmacy and government supplier channels.

Q5. Who are the key influenza vaccine market companies?

Answer: Some of the key influenza vaccine companies are as follows:

Q6. Which influenza vaccine market segment will be the largest in future?

Answer: Lucintel forecasts that inactivated is expected to witness higher growth over the forecast period due to growing demand for these vaccinations given to its safety and effectiveness.

Q7. In influenza vaccine market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness highest growth over the forecast period due to high prevalence of influenza, availability of well-established healthcare system, and high preference for vaccination in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

Table of Contents

1. Executive Summary

2. Global Influenza Vaccine Market : Market Dynamics

3. Market Trends and Forecast Analysis from 2018 to 2030

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

5. Competitor Analysis

6. Growth Opportunities and Strategic Analysis

7. Company Profiles of Leading Players

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â